Le Lézard
Classified in: Health
Subjects: PDT, TRI

Overcoming Resistance and Toxicity Hurdles: PST's Localized Drug Delivery Technology May Unlock Combined MEK/mTOR Inhibition For Multiple KRAS+ Tumors Types


IRVINE, Calif., May 23, 2024 /PRNewswire/ -- Postsurgical Therapeutics, Inc. (PST) today announced the successful completion of an in vivo study of its proprietary injectable gel formulation containing two drugs used to treat several types of KRAS mutated solid tumors. The results demonstrated suppression or elimination of tumors in mice. The drugs were developed and commercialized by others for oral administration.

PST's proprietary controlled release gel formulation of the drugs was administered by intratumoral injection to the target tumors. The drugs used target the MAPK and PI3K pathways using a combination of MEK and mTOR inhibitors, which are important for treatment of several major tumor types. The formulation was shown to be effective, reducing growth or eradicating tumors in several KRAS mutations across multiple cancer cell lines, including pancreatic (Mia PaCa-2, G12C), lung (NCI H441, G12V), colorectal (SW3, G12V), and gastric (AGS, G12D) cancers.

In clinical practice, multiple drugs are often required as resistance to a single drug limits its therapeutic use. However, clinic investigations by others of combinations of these two drugs by oral administration have not been able to determine a safe and effective dose due to cumulative toxicity as reported by Tolcher (Tolcher et al. Annals of Oncology, 58-64 (2015)) and by Nikanjam (Nikanjam et al. J. Hematol. Oncol. Pharm, 19-25 (2023)).

Soonkap Hahn, Ph.D., Chairman, Chief Scientific Officer, and Founder of PST stated that "If clinical trials confirm the results of this study, we believe the resulting product will have the potential to extend the lives of treated patients. We will also investigate the potential reduction in toxicity by local administration."

PST is a development stage company based in Irvine, California. PST uses advanced drug delivery technologies to formulate products with enhanced efficacy and safety for the treatment of solid tumors and other therapy areas.

PST intends to develop and commercialize products based on its technology through collaborations with corporate partners and others.

SOURCE Postsurgical Therapeutics


These press releases may also interest you

16 jun 2024
Mirum Pharmaceuticals, Inc. today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat...

16 jun 2024
Eczema, a skin inflammatory disease that causes dry, itchy and inflamed skin, affects millions worldwide. Eczema is associated with an altered skin microbiome and higher colonization by Staphylococcus aureus. The study, led at New York Medical by...

16 jun 2024
Thousands of participants raised $1.63 million at the 11th annual Journey to Conquer Cancer ? a new record for this event, presented by Starlight Investments benefiting the Princess Margaret Cancer Centre on June 16, 2024. This inclusive family and...

16 jun 2024
Please be advised that the Honourable Patty Hajdu, Minister of Indigenous Services, will make a funding announcement for the Weeneebayko Area Health Authority. Date:  Monday, June 17, 2024Time: 12:00 p.m. (ET) Where:House of Commons Foyer (West...

16 jun 2024
Today, Crisis Prevention Institute (CPI) announced the launch of Reframing Behavior ? its new groundbreaking, subscription-based, schoolwide training program that unpacks the latest neuroscience to help all educators build a more positive, supportive...

16 jun 2024
Positive results from the ECHO Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival...



News published on and distributed by: